行情

EXEL

EXEL

伊克力西斯
NASDAQ

实时行情|Nasdaq Last Sale

22.36
-0.45
-1.97%
盘后: 22.30 -0.06 -0.27% 18:44 08/07 EDT
开盘
23.15
昨收
22.81
最高
23.18
最低
22.25
成交量
272.59万
成交额
--
52周最高
27.80
52周最低
13.67
市值
68.57亿
市盈率(TTM)
23.99
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EXEL价格均价为30.00,最高价位40.00,最低价为22.00。

EPS

EXEL 新闻

更多
Exelixis EPS beats by $0.11, beats on revenue
Exelixis (NASDAQ:EXEL): Q2 Non-GAAP EPS of $0.25 beats by $0.11; GAAP EPS of $0.21 beats by $0.09. Revenue of $259.5M (+8.0% Y/Y) beats by $33.1M. Net prod
seekingalpha · 1天前
Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 75.00% and 11.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1天前
Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Business Wire · 1天前
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 after the markets close. At 5:30 p.m. EDT / 2:30 p.m. PDT, Exelixis management will host a conference call and webcast to
Business Wire · 07/29 20:05
Will Exelixis (EXEL) Gain on Rising Earnings Estimates?
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks · 07/23 16:20
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/22 16:32
EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?
EXEL vs. RGEN: Which Stock Is the Better Value Option?
Zacks · 07/22 15:40

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

EXEL 简况

Exelixis, Inc.是一家生物制药公司。该公司从事开发用于治疗癌症的小分子药物。该公司专注于开发和销售治疗各种肿瘤适应症的多种受体酪氨酸激酶抑制剂卡博替尼。卡博替尼用于治疗进行性及转移性甲状腺髓样癌,并且以“COMETRIQ”品牌出售。该公司通过开发计划评估Cabozantinib,包括晚期肾细胞癌(RCC)和肝细胞癌(HCC)等多个适应症核心研究的45个以上临床试验。其他产品包括Cobimetinib和XL888。Cobimetinib是MEK的有效选择激酶抑制剂,是RAS / RAF / MEK / ERK通路的一个组成部分。 XL888是一种小分子热激蛋白90(HSP90)的口腔抑制剂。XL888是一种分子伴侣蛋白,影响一系列调节蛋白的活性和稳定性。
展开

微牛提供Exelixis, Inc.(NASDAQ-EXEL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EXEL股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易EXEL股票基本功能。